Cerevel soars on first data for muscarinic schizophrenia drugShares in Pfizer spinout Cerevel Therapeutics have more than doubled after it reported positive early-stage results with CVL-231, Share XCerevel soars on first data for muscarinic schizophrenia drughttps://pharmaphorum.com/news/cerevel-soars-on-first-data-for-muscarinic-schizophrenia-drug/
Exscientia starts trials of AI-designed Alzheimer’s drugExscientia has advanced a drug candidate for Alzheimer’s disease into human testing, the third clinical-stage project for the Share XExscientia starts trials of AI-designed Alzheimer’s drughttps://pharmaphorum.com/news/exscientia-starts-clinical-trials-of-ai-designed-alzheimers-drug/
Acadia puts blame on FDA as Nuplazid rejected for dementiaAcadia Pharmaceuticals is butting heads with US regulators again, this time over the FDA’s decision to reject its Share XAcadia puts blame on FDA as Nuplazid rejected for dementiahttps://pharmaphorum.com/news/acadia-blame-fda-nuplazid-rejected-dementia/
